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Abstract
An acceptable live-attenuated dengue virus vaccine candidate should have low potential for transmission by mosquitoes. We have identified
and characterized a mutation in dengue virus type 4 (DEN4) that decreases the ability of the virus to infect mosquitoes. A panel of 1248
mutagenized virus clones generated previously by chemical mutagenesis was screened for decreased replication in mosquito C6/36 cells but
efficient replication in simian Vero cells. One virus met these criteria and contained a single coding mutation: a C-to-U mutation at nucleotide 7129
resulting in a Pro-to-Leu change in amino acid 101 of the nonstructural 4B gene (NS4B P101L). This mutation results in decreased replication in
C6/36 cells relative to wild-type DEN4, decreased infectivity for mosquitoes, enhanced replication in Vero and human HuH-7 cells, and enhanced
replication in SCID mice implanted with HuH-7 cells (SCID-HuH-7 mice). A recombinant DEN4 virus (rDEN4) bearing this mutation exhibited
the same set of phenotypes. Addition of the NS4B P101L mutation to rDEN4 bearing a 30 nucleotide deletion (30) decreased the ability of the
double-mutant virus to infect mosquitoes but increased its ability to replicate in SCID-HuH-7 mice. Although the NS4B P101L mutation decreases
infectivity of DEN4 for mosquitoes, its ability to enhance replication in SCID-HuH-7 mice suggests that it might not be advantageous to include
this specific mutation in an rDEN4 vaccine. The opposing effects of the NS4B P101L mutation in mosquito and vertebrate systems suggest that
the NS4B protein is involved in maintaining the balance between efficient replication in the mosquito vector and the human host.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The mosquito-borne dengue viruses (genus Flavivirus,
family Flaviviridae, serotypes DEN1–DEN4) are the caus-
ative agents of dengue fever (DF) and its more severe
manifestation, dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS). Currently, dengue virus is the most
significant arthropod-borne virus (arbovirus) in humans,
causing an estimated 100 million cases of DF and 500,000
cases of DHF/DSS annually, resulting in enormous morbid-
ity and thousands of deaths (Gubler, 1998). Moreover, the
incidence of DHF is increasing dramatically in the devel-
oping world (Gubler, 2001). The most common risk factor
associated with the emergence of DHF/DSS is the cocircu-
lation of multiple dengue virus serotypes in a community
(Gubler, 2001), since progression to DHF/DSS is more
likely during second infection (Murgue et al., 2000; Vaughn
et al., 2000). At present neither a licensed vaccine nor
antiviral therapy is available for dengue virus.
Because of the association between second infection and
DHF/DSS, an acceptable vaccine must induce immunity to
all four serotypes concurrently and should have a low po-
tential for transmission of the vaccine components by mos-
quitoes. To date, development of tetravalent live-attenuated
vaccine candidates has resulted in uneven attenuation, and
incomplete immunity (Bhamarapravati and Sutee, 2000;
* Corresponding author. Building 50, Room 6515, 50 South Drive,
NIH, Bethesda MD 20892-8007. Fax: 1-301-480-4873.
E-mail address: khanley@niaid.nih.gov (K.A. Hanley).
R
Available online at www.sciencedirect.com
Virology 312 (2003) 222–232 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Science (USA). All rights reserved.
doi:10.1016/S0042-6822(03)00197-1
Kanesa-thasan et al., 2001; Sabchareon et al., 2002), and, in
some cases, wild-type levels of mosquito infectivity (Scho-
epp et al., 1991). Transmission of a live-attenuated tetrava-
lent dengue vaccine by a mosquito has the potential to
increase the level of DHF in a community for two reasons.
First, transmission of dengue virus is not perfectly efficient,
the four dengue serotypes differ in their infectivity for a
particular strain of Aedes mosquito, and Aedes strains differ
in their susceptibility to various serotypes (Rosen et al.,
1985). Thus it is likely that at least some mosquitoes that fed
on a vaccinated individual would transmit only a single
serotype of a tetravalent vaccine. Individuals who were
infected with a single vaccine serotype and subsequently
infected with a different, wild-type serotype of dengue virus
could be at increased risk for DHF. Second, multiple rounds
of mosquito transmission could result in reversion of the
attenuating mutations in vaccine viruses. The risks of un-
controlled transmission of a vaccine virus have been dra-
matically illustrated by the reversion to virulence of the oral
poliovirus vaccine in Haiti and the Dominican Republic
(Kew et al., 2002).
The dengue viruses possess a 10.6-kb, single-stranded, pos-
itive-sense RNA genome that encodes three structural and at
least seven nonstructural proteins. The genome, which codes
for a single polypeptide, is organized as follows: 5-UTR-
C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3 UTR
(UTR: untranslated region; C: capsid; prM: membrane precur-
sor; E: envelope; NS: nonstructural protein) (Rice, 1996). A
deletion that removes nucleotides 10478–10507 of the 3UTR
(30) was previously used to generate vaccine candidate
rDEN430, which is attenuated for rhesus monkeys and hu-
mans (Durbin et al., 2001). In addition, the 30 mutation has
been shown to decrease the ability of DEN4 to disseminate
from the mosquito midgut to the head (Troyer et al., 2001).
However, the 30 mutation does not affect the establishment
of a midgut infection in mosquitoes nor does it altogether
abolish dissemination when a high dose of virus is ingested
(Troyer et al., 2001). Moreover, the effect of the 30 mutation
on mosquito infection by the other three DEN serotypes is not
yet known. To augment the attenuation conferred by30 in the
mosquito vector, we sought to identify and characterize muta-
tions that specifically decrease the ability of DEN4 to infect the
mosquito midgut while promoting efficient replication in Vero
cells, the cell type to be used for vaccine manufacture.
To identify mosquito-attenuation mutations, we utilized
a panel of virus clones generated by chemical mutagenesis
(Blaney et al., 2001). Wild-type recombinant DEN4 virus
rDEN4-2A was grown in the presence of 5-fluorouracil
(5-FU) and 1248 clones were isolated. In the present study
we screened each of these virus clones to identify mutant
viruses that exhibit restricted replication in mosquito C6/36
cells but that retain efficient replication in simian Vero cells.
This is a useful preliminary assay for decreased infectivity
for intact mosquitoes, since reduced replication in cultured
mosquito cells is often, though not always, associated with
reduced infectivity for intact mosquitoes (Huang et al.,
2000). Only one such virus clone was identified and this
mutant exhibited both reduced infectivity for mosquitoes
and significantly enhanced replication in Vero cells and
HuH-7 (human hepatoma) cells. The genetic basis for this
phenotype is a single amino acid change in NS4B.
Results
Identification of small plaque mutant viruses in C6/36 cells
A panel of 1248 virus clones was generated by 5-FU
mutagenesis of rDEN4 in Vero cells (Blaney et al., 2001),
and the efficiency of plaque formation (EOP) and plaque
size of each of these virus clones were determined in C6/36
cells and compared to these phenotypes in Vero cells. While
numerous mutant viruses replicated either well or poorly in
both cell types, none showed decreased EOP in only C6/36
cells (arbitrarily defined as a 1000-fold decrease between
EOP in Vero cells and C6/36 cells). However, one mutant
virus (no. 5) produced plaques that were noticeably smaller
than wild-type in C6/36 cells while maintaining large
plaque size in Vero cells. Mutant virus no. 5 replicated to
high titer (7.0 log10 PFU/ml) in both cells types. After three
rounds of terminal dilution, this virus, designated rDEN4-
2A-5, maintained the plaque size phenotype (Fig. 1) of the
original mutant virus and was studied further. Analysis of
the consensus sequence of the entire genome of rDEN4-
2A-5 revealed that it contained only one coding mutation
and two translationally silent mutations relative to its un-
mutagenized, wild-type, parental virus (Table 1). The single
missense mutation, C to U, at nucleotide 7129 results in a
Pro-to-Leu substitution in amino acid 101 of the NS4B
protein (NS4B P101L), and it thus appeared that this mu-
tation was responsible for the small plaque (sp) phenotype
of rDEN4-2A-5 in C6/36 cells.
To confirm that the NS4B P101L mutation was indeed
responsible for the sp phenotype in C6/36 cells, the mutation
was introduced into a wt DEN4 cDNA clone to generate the
rDEN4-7129 virus. Additionally, to investigate the interaction
between the NS4B P101L mutation and the previously de-
scribed 30 mutation (Durbin et al., 2001; Troyer et al., 2001),
the NS4B P101L was introduced into a DEN4 cDNA carrying
the 30 mutation to generate virus rDEN430-7129. Analysis
of the consensus sequence demonstrated that both rDEN4-
7129 and rDEN430-7129 contained the designated coding
changes along with incidental, silent mutations (Table 1).
Plaque size of these viruses was compared to rDEN4-C6/36, a
recombinant wild-type DEN4 recovered in C6/36 cells that has
a consensus sequence identical to that of the cDNA from
which it was derived. Similar to rDEN4-2A-5, rDEN4-7129
showed reduced plaque size and normal titer in C6/36 cells
relative to rDEN4-C6/36 (Fig. 1). The mean diameter of
rDEN4-C6/36 plaques in C6/36 cells is twice that of rDEN4-
7129, resulting in a fourfold difference in plaque area. Plaque
diameter of rDEN430-7129 was significantly smaller than
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that of rDEN4-7129 (Fig. 1). Moreover, in mammalian cells
(Fig. 1), the plaque diameter of rDEN4-2A-5 and rDEN4-
7129 was approximately twofold (Vero) and threefold
(HuH-7) greater than that of rDEN4-C6/36, translating into
a fourfold greater area in Vero cells and an eightfold greater
area in HuH-7 cells. In Vero cells, rDEN430-7129 showed
an intermediate plaque diameter between rDEN4-C6/36 and
rDEN4-7129; in HuH-7 cells the plaque diameter of
rDEN430-7129 was not different from that of rDEN4-
7129.
To test the relationship between plaque size and replica-
tion in tissue culture, we compared the kinetics and magni-
tude of replication of rDEN4-C6/36, rDEN4-7129, and
rDEN430-7129 in C6/36, Vero, and HuH-7 cells (Fig. 2).
Viruses carrying the NS4B P101L mutation showed a sig-
nificant decrease in replication kinetics in C6/36 cells and a
significant increase in replication kinetics in Vero and
HuH-7 cells relative to rDEN4-C6/36. Replication of
rDEN430-7129 was comparable to that of rDEN4-7129 in
HuH-7 cells and lower than rDEN4-7129 in Vero and C6/36
cells. These findings reflect the plaque size differences in
the specified cell types.
Fig. 1. Plaque size of rDEN4-C6/36, rDEN4-2A-5, rDEN4-7129, and rDEN430-7129 in C6/36, Vero, and HuH-7 cells. Monolayers of confluent cells were
infected with the indicated viruses and incubated for 5 days, and resulting plaques were visualized by immunoperoxidase staining. Values below each well
represent the mean plaque diameter in mm standard error (n 36 plaques per virus). For each cell type, plaque sizes were compared among the four viruses
using a Tukey–Kramer post-hoc test; letters in parentheses next to mean plaque size indicate significantly different groups within each cell type, such that
groups which share a letter are not significantly different and groups which do not share a letter are significantly different (P  0.05).
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Mosquito infectivity of small plaque mutant viruses
To determine whether reduced replication in C6/36 mos-
quito cells in tissue culture was an indication of reduced in-
fectivity for intact mosquitoes, the percentage of Aedes aegypti
infected after feeding on bloodmeals containing either mutant
viruses bearing the NS4B P101L mutation or wild-type DEN4
viruses was determined (Fig. 3). Two wild-type viruses were
used in this comparison: rDEN4-2A-13, derived from rDEN4-
2A, is used for comparison with rDEN4-2A-5; rDEN4, derived
from plasmid p4, is used for comparison with rDEN4-7129
and rDEN430. rDEN4-2A-13 and rDEN4 were both derived
from cDNA plasmids encoding identical virus polyproteins,
yet each accumulated different incidental mutations during
passage in cell culture (Blaney et al., 2001; Durbin et al.,
2001). The data presented in Fig. 3 identify DEN4 viruses with
three levels of infectivity. Wild-type DEN4 viruses (rDEN4-
2A-13 and rDEN4) caused both a high percentage of total
infections (infection of the midgut, irrespective of dissemina-
tion to the head) and a high percentage of disseminated infec-
tions of mosquitoes at doses of approximately 104.0 PFU. Virus
carrying just the 30 mutation (rDEN430) caused a high
percentage of total infections at a similar dose, but no dissem-
inated infections, confirming previous observations (Troyer et
al., 2001). Viruses carrying the NS4B P101L mutation caused
a low percentage of total infections. Pairwise Fisher exact tests
were used to compare the infectivity of each virus containing
the NS4B P101L mutation to the comparable wild-type virus at
the highest dose of each: rDEN4-2A-13 vs rDEN4-2A-5, n 
39, P  0.001; rDEN4 vs rDEN4-7129, n  68, P  0.001;
rDEN430 vs rDEN430-7129, n  30, P  0.001.
Since the NS4B P101L mutation prevented the virus
from infecting the midgut of Ae. aegypti, it was not possible
using this method to determine whether it also caused re-
striction in salivary gland infection. To assess this pheno-
type, we inoculated a subset of the viruses intrathoracically
into Toxorhynchites splendens mosquitoes, thus bypassing
the midgut. As shown in Table 2, both rDEN4-2A-5 and
rDEN4-7129 infected a much lower percentage of mosquito
heads (0 and 25%, respectively), following intrathoracic
inoculations than their wild-type parent viruses (83 and
100%, respectively), and in the case of rDEN4-2A-5 this
difference was significant.
Temperature sensitivity and mouse attenuation phenotypes
of NS4B P101L viruses
Since the goal of this study was to identify mutations
conferring attenuation in mosquitoes that might be useful to
include in an rDEN4 vaccine, we tested each of the viruses
containing the NS4B P101L mutation for three phenotypes
associated with attenuation in humans: temperature sensitivity
(ts) in Vero and HuH-7 cells, decreased replication in suckling
mouse brain, and decreased replication in SCID mice trans-
planted with HuH-7 cells (SCID-HuH-7) (Blaney et al., 2001,
2002). None of the NS4B P101L mutant viruses was ts in
either Vero or HuH-7 cells or restricted in replication in suck-
ling mouse brain (Table 3). However, in SCID-HuH-7 mice,
rDEN4-2A-5 and rDEN4-7129 showed a small but significant
enhancement of replication relative to wild-type DEN4 (Fig.
4). This enhancement in replication conferred by the NS4B
P101L mutation was reduced by the 30 mutation, although
not to a level as low as that of rDEN430 (Fig. 4).
Discussion
The goal of this study was to identify mutations that
decreased infectivity of dengue virus for mosquitoes. Such
mutations could be useful to restrict transmission of a den-
gue virus vaccine from vaccinees to mosquitoes. Of 1248
DEN4 virus clones screened, only one showed mosquito-
specific attenuation in tissue culture, and this virus con-
tained a single missense mutation in the NS4B gene. Small
plaque size in mosquito cells in tissue culture was indicative
of both decreased replication in mosquito cells in tissue
Table 1
Nucleotide and amino acid differences among viruses utilized in this study
Virus Nucleotide position Gene/Region Nucleotide changea Amino acid change
rDEN4-2A-5 7129 NS4B C U Pro Leu
7359 NS4B C U None
9047 NS5 U  C None
rDEN4-7129 7124 NS4B C U None
6521 NS4A U C None
7129–7130 NS4B CA UU Pro Leu
rDEN430-7129 7124 NS4B C U None
7129–7130 NS4B CA UU Pro Leu
10475 3 UTR Deletionb None
10478–10507 3 UTR Deletionc None
rDEN4-C6/36 — — None None
a The consensus sequence is compared to the cDNA from which each virus was derived. Translationally silent nucleotide changes incorporated into the
mutagenesis primer in addition to the NS4B P101L mutation are not shown.
b 30 comutation (Durbin et al., 2001).
c 30 mutation (Durbin et al., 2001).
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culture and decreased infectivity for intact mosquitoes. Ad-
dition of the NS4B P101L mutation to DEN4 decreased
replication of the rDEN4 derivative in C6/36 cells. More-
over, viruses carrying the NS4B P101L mutation were sig-
nificantly restricted in their ability to infect the midgut of
Ae. aegypti fed an infectious bloodmeal and to infect the
head of Tx. splendens inoculated intrathoracically. Thus a
single amino acid change in the NS4B gene strongly atten-
uated DEN4 for mosquitoes. The level of reduction of
infectivity for intact mosquitoes appears far greater than the
small effect on replication in C6/36 cells in tissue culture.
Studies of other flaviviruses have detected an association
between mutations in NS4B and decreased mosquito infectiv-
ity. A yellow fever mutant virus generated by cell passage that
was incapable of infecting mosquitoes was shown to carry
multiple mutations in the NS4B gene, along with mutations in
other genes (Dunster et al., 1999). Japanese encephalitis vac-
cine virus SA14-2-8, which shows reduced mosquito infectiv-
ity, was shown to carry one mutation in the NS4B gene, along
with mutations in other genes (Ni et al., 1995). However, in
neither case has the contribution of the NS4B mutations to the
mosquito phenotype been defined. Conversely, several defined
mutations outside of NS4B have been shown to decrease
infectivity of dengue virus for mosquito cells in tissue culture.
A small set of mutations (mutF) in the 3 UTR (Markoff et al.,
2002; Zeng et al., 1998) and, independently, a combination of
one mutation in the 5UTR and one mutation in NS1 (Butrapet
et al., 2000) are known to reduce replication in mosquito C6/36
cells. Among other arboviruses, mosquito infectivity has been
studied most intensely in the alphaviruses (Strauss and Strauss,
1994). Mutations with host-specific effects have been docu-
mented for Sindbis virus, in which mutations in the viral
polymerase (Lemm et al., 1990), 3 UTR (Kuhn et al., 1990),
and glycoproteins (Boehme et al., 2000) result in loss of in-
fectivity for mosquito cells in tissue culture. However, care
must be taken in interpreting these results, since at least one
study has shown that Sindbis viruses that replicate poorly in
mosquito cells in cell culture nonetheless produce normal
yields of virus in intact mosquitoes (Stollar and Hardy, 1984).
Several evolutionary studies have investigated whether arbo-
viruses passaged exclusively in vertebrate cells tend to lose
fitness in invertebrate cells (reviewed in Cooper and Scott,
2001). Only one of these studies has documented a loss of
fitness in mosquito cells for virus passaged in BHK (hamster)
cells (Weaver et al., 1999).
In addition to its effect on mosquito infectivity, the NS4B
P101L mutation also had pleiotropic effects on replication in
mammalian cells. Addition of this mutation to DEN4 enhanced
both plaque size and level of replication in both simian Vero
and human HuH-7 cells relative to that of wild-type DEN4.
Thus, the NS4B P101L mutation acts as a “trade-off” mutation
that improves replication in mammalian systems at the cost of
reduced replication in mosquitoes. Since little is known about
the function of NS4B, it is impossible at this time to infer a
mechanism by which the NS4B P101L mutation may effect
this trade-off. The fact that the phenotype conferred by the
mutation is host-specific suggests that the mutation may affect
the interaction between NS4B and host cell factors unique to
each host type. The attenuation in mosquitoes conferred by the
NS4B P101L mutation may be useful in investigations of the
mechanism of dengue virus infection of mosquitoes and spe-
cifically the role of NS4B in this process.
The action of the NS4B P101L mutation may also provide
insight into the impact of host alternation on dengue virus
evolution. Dengue virus, similar to many arthropod-borne
RNA viruses (notably flaviviruses and alphaviruses), evolves
at rates 10-fold slower than non-arthropod-borne viruses (Scott
et al., 1994; Zanotto et al., 1996). One hypothesis for this
Fig. 2. Replication kinetics of rDEN4-C6/36, rDEN4-7129, and rDEN430-
7129 in Vero, HuH-7, and C6/36 cells. Three flasks of each cell type were
infected with the indicated virus at an m.o.i. of 0.01. One-milliliter samples of
tissue culture medium were removed at the designated time points, and the
levels of virus replication were determined by plaque titration in Vero cells; the
limit of detection was0.7 log10PFU/ml. Replication of the three viruses was
compared in each cell type separately using a repeated-measures ANOVA and
a Tukey–Kramer post-hoc test. Letters in parentheses next to each virus
designation indicate significantly different groups such that groups which
share a letter are not significantly different and groups which do not share a
letter are significantly different (P 0.05); ordering of letters indicates relative
level of replication, with “A” indicating the highest level.
226 K.A. Hanley et al. / Virology 312 (2003) 222–232
Fig. 3. Percentage of mosquitoes with detectable dengue virus in the midgut (Total Infections) or midgut and head (Disseminated Infections). Mosquitoes were assayed 21
days after being fed an infectious bloodmeal and dengue virus antigen in midgut and head tissues was identified by IFA. The virus dose was calculated by assuming that
each mosquito takes a 2 l bloodmeal. Sample sizes are listed above each bar; circles indicate that no mosquitoes were infected at a corresponding dose.
pattern is that host alternation constrains evolution in arbovi-
ruses (Scott et al., 1994). The reasoning that underlies this idea
is that the need to replicate in the very different environments
of arthropod and vertebrate hosts causes arboviruses to evolve
to a compromise genotype that allows them to replicate in each
environment but does not maximize fitness in either. The
NS4B P101L mutation appears to reveal such a compromise,
since evolution to this genotype in DEN4 would probably
improve fitness in the mammalian host, but would damage
transmission by the mosquito vector.
The ability of the NS4B P101L mutation to act as a
safeguard against mosquito transmission is clear, but its
utility for an rDEN4 vaccine candidate depends upon its
interaction with other attenuating mutations in the virus.
Both the NS4B P101L mutation and 30 have similar
effects on mosquito infectivity, ts phenotypes in cell culture,
and attenuation in suckling mouse brain; combining the two
mutations in rDEN430-7129 did not change these pheno-
typic effects. In contrast, rDEN430 is attenuated in repli-
cation in SCID-HuH-7 mice, whereas rDEN4-7129 is en-
hanced relative to rDEN4. Combination of the two
mutations resulted an intermediate phenotype and similar
levels of replication to rDEN4. In human clinical trials,
rDEN430 showed some residual hepatotoxicity when 105
PFU virus was administered (Durbin et al., 2001). SCID-
HuH-7 mice are a model for virus replication in the liver,
and a decrease in attenuation for rDEN430 in this system
would therefore be undesirable. At this time the NS4B P101L
is not being incorporated into rDEN430 to modify the vac-
cine. Since the 30 mutation itself significantly restricts mos-
quito infectivity, this vaccine candidate is already limited in its
potential for transmission (Troyer et al., 2001).
The NS4B P101L mutation may be useful in one of the
other three DEN serotypes or for the development of an
Table 2
The NS4B P101L mutation identified in rDEN4-2A-5 and inserted into
rDEN4-7129 causes a significant decrease in DEN4 infectivity for
Toxorhynchites splendens inoculated intrathoracically
Virus tested Dose inoculated
(log10PFU)a
No. mosquitoes
tested
% Infectedb,c
rDEN4 3.3 6 83
2.3 7 57
1.3 6 0
MID50  2.3
rDEN4-2A-13 4.0 5 100
3.0 9 89
2.0 6 50
MID50  2.4
rDEN4-7129 3.6 8 25
2.6 4 0
MID50  4.3d
rDEN4-2A-5 3.4 9 0
MID50  4.4e
a Amount of virus inoculated in a 0.22 l dose.
b Percentage of mosquitoes with detectable dengue virus in head tissue;
mosquitoes were assayed 14 days postinoculation, and dengue virus anti-
gen was identified by IFA.
c Pairwise Fisher exact tests were used to compare each virus containing
the NS4B P101L mutation with the appropriate wild-type virus. Because
doses were not identical, the total number infected for each virus contain-
ing NS4B P101L was compared to the total number infected for the
comparable wild-type at the next lower dose. Results for the two compar-
isons were as follows: rDEN4-2A-13 vs rDEN4-2A-5, n  18, P  0.001;
rDEN4 vs rDEN4-7129, n  14, P  0.1.
d When infection was detected, but did not exceed a frequency of 50%
at the highest dose of virus ingested, the MID50 was estimated by assuming
that a 10-fold more concentrated virus dose would infect 100% of the
mosquitoes.
e When no infection was detected, the MID50 was assumed to be greater
than a 10-fold higher dose of virus than the one used.
Table 3
The NS4B P101L mutation present in rDEN4-2A-5 and inserted into rDEN4-7129 and rDEN430-7129 does not confer temperature sensitivity in Vero
or HuH-7 cells and does not affect replication in suckling mouse brain
Virusa Mean virus titer (log10PFU/ml) at indicated temperature (°C) Replication in suckling mouse brainc
Vero HuH-7 Mean virus
titer  SE
(log10PFU/g brain)
Mean log
reduction
from wtd35 37 38 39 
b 35 37 38 39 
rDEN4-2A-13 7.3 7.5 7.5 6.8 0.5 8.0 7.9 7.5 6.8 1.2 6.2 0.1 —
rDEN4-2A-5 6.7 7.3 7.3 6.5 0.2 7.5 7.7 7.0 6.0 1.5 6.2 0.3 0.0
rDEN4 7.3 7.5 7.6 7.0 0.3 8.0 7.6 7.8 7.3 0.7 5.6 0.1 —
rDEN430 6.6 6.6 6.5 6.5 0.1 7.4 6.9 7.0 6.4 1.0 5.5 0.5 0.1
rDEN4-7129 7.3 6.9 6.9 7.0 0.3 7.6 7.3 7.3 6.3 1.3 5.7 0.1 () 0.1
rDEN430-7129 6.3 6.8 6.6 5.3 1.0 7.3 6.9 6.9 3.9 3.4 5.1 0.5 0.5
a Each mutant virus was compared to the recombinant wild-type virus from which it was derived.
b Reduction in titer (log10PFU/ml) at 39°C compared to permissive temperature (35°C). Temperature sensitivity is defined in this study as a 2.5 or 3.5 log10PFU/ml
reduction in titer in Vero or HuH-7 cells, respectively, at the indicated temperatures when compared to permissive temperature (35°C) (Hanley et al., 2002).
c Groups of six suckling mice were inoculated intracerebrally with 104 PFU virus in a 30 l inoculum. The brain was removed 5 days later and homogenized,
and virus titer was determined in Vero cells.
d Determined by comparing mean viral titers in mice inoculated with sample virus and concurrent wt controls (n  6). The attenuation phenotype is defined as
a1.7 log10PFU/g decrease in virus replication in suckling mouse brain. A minus () sign indicates an increase in replication relative to the wt control. A one-sample
sign test was used to determine whether any of the mutant viruses showed a mean reduction or increase in titer significantly different from 0 (df  5; P  0.3 for
each of the four comparisons).
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inactivated tetravalent vaccine. DEN1, DEN2, and DEN3
all possess a Pro residue at the position corresponding to
amino acid position 101 in DEN4 NS4B (Chang, 1997).
Interestingly, Japanese encephalitis virus, Kunjin virus, and
West Nile virus each possess a Leu at that position, the same
amino acid encoded by the NS4B P101L mutation, yet are
efficiently transmitted by mosquitoes. This may indicate
that it is not the presence of Leu per se that damages
mosquito infectivity but rather its effect on protein structure
of NS4B. We are currently in the process of introducing a
corresponding Pro-to-Leu mutation in the NS4B gene of the
other three DEN serotypes to determine whether its effect
on mosquito infection is transferable to each DEN serotype.
The NS4B P101L mutation falls into a cluster of mutations
in the DEN4 NS4B gene that confer enhanced ability to rep-
licate in Vero cells; these have been termed Vero cell adapta-
tion mutations (Blaney et al., 2001, 2002). These Vero cell
adaptation mutations are similar to the NS4B P101L mutation
in that both confer enhanced replication in Vero cells in tissue
culture. However, NS4B P101L is unique in both its ability to
Fig. 4. Mean difference (log10PFU/ml serum) of peak level of replication of rDEN4-2A-5, rDEN4-7129, rDEN430-7129, and rDEN430 relative to a
concurrent wild-type control virus (rDEN4) in SCID-HuH-7 mice. Groups of SCID-HuH-7 mice were inoculated directly into the tumor with 104 PFU of
virus. Serum was collected on days 6 and 7 and titer determined in Vero cells. Values for rDEN4-2A-5 and rDEN430 represent results from a single
experiment with one concurrent control. Values for rDEN430 and rDEN4-7129 represent data from two or three separate experiments, respectively. In these
latter two cases, data were combined across experiments only after values were compared between experiments and found not to be significantly different
(rDEN430, Student’s t-test, df  1, P  0.7; rDEN4-7129, ANOVA, df  2, P  0.9). Asterisks (*) indicate that the mean log10 difference is significantly
different from 0 (one-sample t-test, P  0.05).
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decrease plaque size in C6/36 cells and its ability to enhance
replication in SCID-HuH-7 mice. Nonetheless, the proximity
of these mutations and their similar effect on replication in
Vero cells suggests that at least some of the Vero cell adapta-
tion mutations may reduce infectivity for intact mosquitoes,
particularly since the large reduction in mosquito infectivity
conferred by the NS4B P101L mutation was associated with
only a small reduction in replication in C6/36 cells. Impor-
tantly, if one or more of these Vero cell adaptation mutations
does suppress mosquito infectivity, this effect would be de-
coupled from enhancement of replication in SCID-HuH-7
mice. Preliminary studies indicate that certain Vero cell adap-
tation mutations do indeed decrease the mosquito infectivity of
rDEN4, and these are being investigated further.
Vero cell adaptation mutations have two additional features
which are desirable in a vaccine candidate. First, they enhance
virus yield in Vero cells, the intended substrate for vaccine pro-
duction, and thus, could render the production of live-attenuated
vaccine, or even inactivated vaccines, more cost-effective. This is
a crucial property for a vaccine intended for use in countries of the
developing world. Second, although each of these Vero adaptation
mutations are point mutations, they are likely to be extremely
stable during vaccine manufacture, because they give a selective
advantage in Vero cells. Competition between mutant and rever-
tant viruses plays out very differently for attenuating mutations
and adaptation mutations: in the former case viruses that lose the
mutation have a competitive advantage and spread through the
population, but in the case of adaptation mutations, viruses that
lose the mutation are at a disadvantage and are lost from the
population. Nevertheless, the stability of these mutations can be
further enhanced when they are added to a recombinant virus by
creating more than one nucleotide change to specify the mutation,
as was done for rDEN4-7129 and rDEN430-7129. The suffi-
ciency of the NS4B P101L mutation for Vero cell adaptation is
demonstrated by the fact that none of the three viruses carrying
this mutation accrued any additional mutations in either the struc-
tural proteins or the untranslated regions. Another Vero cell ad-
aptation mutation, 7153, was incorporated into vaccine candidate
rDEN430 as an incidental mutation that occurred during early
passages of the virus in Vero cells, and this mutation proved to be
stable and safe in humans (Durbin et al., 2001).
Methods and materials
Cells and viruses
Vero cells (African green monkey kidney) were main-
tained at 37°C in an atmosphere of 5% CO2 in VP-SFM
(Gibco, Grand Island, NY) supplemented with 2 mM L-
glutamine (Gibco) and 0.05 mg/ml gentamicin (Gibco).
HuH-7 cells (Nakabayashi et al., 1982) were maintained at
37°C in an atmosphere of 5% CO2 in D-MEM/F-12 (Gibco)
supplemented with 10% fetal bovine serum (FBS), 1 mM
L-glutamine, and 0.05 mg/ml gentamicin. C6/36 cells
(Aedes albopictus mosquito cells) were maintained at 32°C
in an atmosphere of 5% CO2 in MEM (Gibco) containing
10% FBS, 2 mM L-glutamine, 2 mM nonessential amino
acids (Gibco), and 0.05 mg/ml gentamicin.
Each of 1248 virus clones generated using 5-fluoroura-
cil mutagenesis of rDEN4-2A (Blaney et al., 2001) was
titered in C6/36 cells. Confluent C6/36 monolayers on 24-
well plates were inoculated in duplicate with serial 10-fold
dilutions of virus, incubated under the conditions described
above for 2 h, and overlaid with OptiMEM (Gibco) con-
taining 0.8% methylcellulose, and supplemented with 2%
FBS, 2 mM glutamine, and 0.05 mg/ml gentamycin. Plates
were further incubated for 5 days and then immunostained
as previously described (Durbin et al., 2001). The titer of
each virus clone in C6/36 cells (log10PFU/ml) and in Vero
cells (TCID50/ml) was compared. Mutant virus no. 5, which
showed small plaque size in C6/36 cells, was biologically
cloned by three rounds of terminal dilution in Vero cells
followed by an additional amplification in Vero cells using
methods previously described (Hanley et al., 2002). The
resulting mutant virus was designated rDEN4-2A-5.
The wild-type DEN4 viruses used in this study were gen-
erated from either the 2A cDNA or the p4 cDNA, a modified
version of 2A in which selected restriction enzyme sites have
been either ablated or introduced through translationally silent
nucleotide substitutions (Durbin et al., 2001; Lai et al., 1991).
Therefore 2A, and consequently p4, both encode the same
polyprotein of the parent virus DEN4 strain 814669 (Dominica
1981). One wild-type virus, rDEN4-2A-13, was generated by
passaging virus rDEN4-2A, derived from cDNA 2A, in Vero
cells in parallel with the 5-fluorouracil-treated virus clones
(Blaney et al., 2001). Therefore rDEN4-2A-13 is used for
comparison with rDEN4-2A-5, a 5-fluorouracil-treated virus
clone. rDEN4 was derived from the cDNA p4 (Durbin et al.,
2001; Lai et al., 1991) and amplified via one additional passage
in Vero cells. rDEN4 is used for comparison with rDEN430
(Durbin et al., 2001), rDEN4-7129, and rDEN430-7129.
Both rDEN-2A-13 and rDEN4 accumulated different
sets of incidental mutations during passage. To generate a
wild-type DEN4 that did not contain any mutations and
could be used in plaque size and multicycle replication
assays, rDEN4-C6/36 was derived from cDNA p4 and
cloned in C6/36 cells (J.E. Blaney et al., unpublished re-
sults). Sequence analysis verified that the whole genomic
consensus sequence rDEN4-C6/36 exactly matches its pre-
dicted sequence derived from p4 (Table 1).
Vaccine candidate rDEN430 was derived from plasmid
p430, a cDNA clone containing a deletion of nucleotides
10,478–10,507 in the 3 UTR, (Durbin et al., 2001; Men et
al., 1996). GenBank Accession Nos. (virus: accession num-
ber) were previously assigned as follows: 814669:
AF326573, rDEN4: AF326825, rDEN430: AF326827.
rDEN4-7129 and rDEN430-7129 were generated via site-
directed mutagenesis (Kunkel, 1985) as previously described
(Hanley et al., 2002). Briefly, a subclone suitable for mutagen-
esis was derived from full-length DEN4 plasmid p4 by diges-
tion with restriction enzymes PmlI and XmaI at nucleotide
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positions 6318 and 7444, respectively. This fragment was then
subcloned into a modified pUC vector and site-directed mu-
tagenesis was performed. The primer used to create the NS4B
P101L mutation was 7112-CTATTCTGAAGTtAACttAA-
CAACCTTGAC-7141 with lower case indicating changes
from wild-type sequence. The T substitution at nucleotide
7124 creates a translationally silent HpaI restriction site useful
for screening mutant plasmids. The TT pair of substitutions at
nucleotides 7128–7129 create the Pro-to-Leu codon change.
Two nucleotides in this codon were altered to make the mu-
tation more resistant to reversion. Restriction enzyme frag-
ments bearing the NS4B P101L mutation were cloned back
into the full-length p4 and p430 plasmids, each of which was
sequenced to confirm the presence of the desired mutation.
5-Capped RNA transcripts were synthesized in vitro from the
mutagenized cDNA templates, transfected in Vero cells, and
biologically cloned by two rounds of terminal dilution in Vero
cells (Blaney et al., 2002). To avoid selection against the
intended small plaque phenotype of the recombinant viruses,
transfection and terminal dilution were performed in Vero cells
rather than C6/36 cells. The resulting viruses were designated
rDEN4-7129 and rDEN430-7129. Each virus was com-
pletely sequenced to ascertain whether any incidental muta-
tions had occurred during transfection and cloning.
Plaque size and multicycle replication kinetics
The plaque size and multicycle replication kinetics of
rDEN4-7129 and rDEN430-7129 were compared to that
of rDEN4-C6/36 in C6/36, Vero, and HuH-7 cells. To
measure plaque size, serial threefold dilutions of the indi-
cated viruses were inoculated in triplicate onto confluent
Vero, HuH-7, and C6/36 cell monolayers in 24-well plates.
After incubation at 37°C (Vero) or 32°C (C6/36) for 2 h,
monolayers were overlaid with medium containing 0.8%
methylcellulose. Following incubation for 5 days, plaques
were visualized by immunoperoxidase staining and digitally
photographed. For each of the virus-infected wells, the
diameter of 36 well-isolated plaques were measured on the
digital image using Adobe Photoshop.
To determine replication kinetics, confluent cell monolayers
in 25-cm2 tissue-culture flasks were infected with virus at a
multiplicity of infection (M.O.I.) of 0.01 in a 1.5-ml inoculum.
After a 2-h incubation at 37°C, cell monolayers were washed
three times in PBS and 5 ml of culture medium supplemented
with 2% FBS was added. A 1-ml aliquot of tissue culture
medium was removed (0 h time point) and replaced with 1 ml
of fresh medium. At designated time points, additional samples
of tissue culture medium were removed (with fresh medium
replacement), clarified by centrifugation, and frozen at70°C.
Virus titer at each time point was determined by plaque titra-
tion in Vero cells.
Mosquito maintenance and infection
Methods for the maintenance of Ae. aegypti and Tx. splendens
mosquitoes, the infection of Ae. aegytpi via an infectious blood-
meal, and the infection of Tx. splendens via intrathoracic inocu-
lation have been previously described (Troyer et al., 2001). Head
and midgut preparations of Ae. aegypti and head preparations of
Tx. splendens were made on glass slides as previously described
(Sumanochitrapon et al., 1998; Troyer et al., 2001). Immunoflu-
orescence assay (IFA) was conducted as described previously
(Troyer et al., 2001) except that hyperimmune mouse ascites fluid
specific for DEN-4 diluted 1/100 in PBS–Tween 20 (0.05%) was
used as the primary antibody. The infectious dose required to
infect 50% of mosquitoes (MID50) was determined by the method
of Reed and Muench (1938).
Characterization of attenuation phenotypes
Viruses were screened for ts phenotype by assessing
plaque formation at permissive (35°C) and various restric-
tive temperatures (37, 38, and 39°C) in Vero and HuH-7 cell
monolayers in 24-well plates as described (Hanley et al.,
2002). The replication of viruses was evaluated in Swiss
Webster suckling mice (Taconic, Germantown, NY) using
groups of six 1-week-old mice that were inoculated intra-
cerebrally with a 30 l inoculum containing 104 PFU of
virus as previously described (Blaney et al., 2001; Hanley et
al., 2002). The replication of viruses in SCID mice trans-
planted with HuH-7 cells (SCID-HuH-7 mice) was deter-
mined as described by Blaney et al., (2002). Briefly, four to
six-week-old SCID mice (Tac:Icr:Ha(ICR)-Prkdcscid) (Tac-
onic) were injected intraperitoneally with 107 HuH-7 cells
suspended in 200 l phosphate-buffered saline. Five to six
weeks after transplantation, tumors were detected in the
peritoneum and mice were infected by direct inoculation
into the tumor with 104 PFU of virus in 50 l Opti-MEM.
Serum for virus titration was obtained by tail-nicking on
days 6 and 7 postinfection, and virus titer was determined
by plaque assay in Vero cells. Tumors were excised and
weighed to confirm uniformity of the experimental groups.
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